This memorandum outlines the principal terms for the Series A-1 Preferred Stock financing of Angiocrine Bioscience, Inc. It includes details on the offering terms, terms of the Series A-1 Preferred Stock, and terms of the Preferred Stock Purchase Agreement. The document specifies the investors, securities to be issued, price, and conditions for closing. It also covers the rights and obligations of the Preferred Stock, including dividends, liquidation preference, conversion rights, and voting rights. The memorandum is non-binding and intended as a summary of proposed terms.
documents/EFTA00292514.pdf
{}